- Home
- MVST vs CHRS Comparison
MVST vs CHRS Comparison
Compare MVST & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- CHRS
- Stock Information
- Founded
- MVST 2006
- CHRS 2010
- Country
- MVST United States
- CHRS United States
- Employees
- MVST N/A
- CHRS 235
- Industry
- MVST Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVST Miscellaneous
- CHRS Health Care
- Exchange
- MVST Nasdaq
- CHRS Nasdaq
- Market Cap
- MVST 182.8M
- CHRS 191.3M
- IPO Year
- MVST N/A
- CHRS 2014
- Fundamental
- Price
- MVST $2.39
- CHRS $1.66
- Analyst Decision
- MVST Buy
- CHRS Strong Buy
- Analyst Count
- MVST 3
- CHRS 4
- Target Price
- MVST $3.33
- CHRS $5.38
- AVG Volume (30 Days)
- MVST 17.9M
- CHRS 3.2M
- Earning Date
- MVST 11-12-2024
- CHRS 11-06-2024
- Dividend Yield
- MVST N/A
- CHRS N/A
- EPS Growth
- MVST N/A
- CHRS N/A
- EPS
- MVST N/A
- CHRS N/A
- Revenue
- MVST $370,989,000.00
- CHRS $304,340,000.00
- Revenue This Year
- MVST $19.19
- CHRS $2.47
- Revenue Next Year
- MVST $29.35
- CHRS N/A
- P/E Ratio
- MVST N/A
- CHRS N/A
- Revenue Growth
- MVST 39.03
- CHRS 44.19
- 52 Week Low
- MVST $0.15
- CHRS $0.66
- 52 Week High
- MVST $2.86
- CHRS $3.13
- Technical
- Relative Strength Index (RSI)
- MVST 65.98
- CHRS 60.93
- Support Level
- MVST $1.95
- CHRS $1.35
- Resistance Level
- MVST $2.86
- CHRS $1.58
- Average True Range (ATR)
- MVST 0.40
- CHRS 0.15
- MACD
- MVST 0.06
- CHRS -0.03
- Stochastic Oscillator
- MVST 73.60
- CHRS 77.50
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.